Please login to the form below
Glybera
This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.
Bluebird puts €1.57m price on gene therapy Zynteglo
Zynteglo won't be the first ever 1m plus gene therapy launched in Europe - that distinction went to UniQure's rare disease treatment Glybera, which was launched in 2012.
Latest news
-
UniQure gets speedy US review for Huntington’s gene therapy
a-year Glybera back in 2012.
-
J&J bolsters gene therapy unit with $100m MeiraGTx deal
In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons.
-
AZ makes gene therapy move with 4DMT alliance
While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut
-
UniQure’s starts pivotal haemophilia B gene therapy trial
UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
-
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum
Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
More from news
Approximately 3 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Assessing the risks in annuity pricing models
Three others (ChondroCelect, PROVENGE and Glybera) were withdrawn, partly due to challenges associated with reimbursement.
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera.
-
Bluebird Bio: on the cusp of a gene therapy revolution
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... That means gene products hitting that Glybera
-
Health on instalment
Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
-
Rare diseases: meeting the challenge
Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Basilea's Hans Christian Rohde takes up commercial role at uniQure
In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Solaris Health looks at the gene therapy revolution
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Consultant
-
competitive salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- NantKwest rockets on promising pancreatic cancer data
- Welcome to the Communique Awards - Communiqué Awards 2018
- Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
- Newly-listed BioNTech buys Neon to boost cell therapy assets
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
- Digital therapeutics and their impact on society
- Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?...
Quick links
Infographics
